NCT06472089 BMT-CARE: Psychosocial Intervention for Transplant Caregivers
| NCT ID | NCT06472089 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Massachusetts General Hospital |
| Condition | Bone Marrow Transplant Complications |
| Study Type | INTERVENTIONAL |
| Enrollment | 800 participants |
| Start Date | 2025-01-10 |
| Primary Completion | 2028-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 800 participants in total. It began in 2025-01-10 with a primary completion date of 2028-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to evaluate whether a psychological intervention (BMT-CARE) is effective at improving the quality of life in caregivers and patients treated with hematopoietic cell transplant compared to usual care, and to identify critical facilitators and barriers for BMT-CARE implementation and adoption.
Eligibility Criteria
Caregiver Inclusion Criteria: * Adult caregivers (≥18 years) relative or friend of a patient identified as living with them or having in-person contact with them at least twice a week. * Caregiver of a patient receiving allogeneic or autologous HCT for the treatment of cancer. * Ability to read and respond to survey questions in English, Spanish or with minimal assistance from an interpreter. Caregiver Exclusion Criteria: * Caregivers of patients undergoing HCT for a benign hematologic condition or undergoing outpatient HCT. * Caregivers with a major untreated psychiatric or cognitive condition which the treating oncology clinicians believes interferes with the capacity to provide informed consent. * Caregivers of patients who have already undergone HCT within the past 5 years Patient Inclusion Criteria: * Adult patients (≥18 years) with a hematologic malignancy and planned admission for autologous or allogeneic HCT. * Ability to respond to questions in English, Spanish, or with minimal assistance from an interpreter.
Contact & Investigator
Areej El-Jawahri, MD
PRINCIPAL INVESTIGATOR
Massachusetts General Hospital
Frequently Asked Questions
Who can join the NCT06472089 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Bone Marrow Transplant Complications. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06472089 currently recruiting?
Yes, NCT06472089 is actively recruiting participants. Contact the research team at ael-jawahri@mgb.org for enrollment information.
Where is the NCT06472089 trial being conducted?
This trial is being conducted at Birmingham, United States, Tampa, United States, Boston, United States.
Who is sponsoring the NCT06472089 clinical trial?
NCT06472089 is sponsored by Massachusetts General Hospital. The principal investigator is Areej El-Jawahri, MD at Massachusetts General Hospital. The trial plans to enroll 800 participants.